Read + Share
Rundquist S, Sachs MC, Eriksson C, Olen O, et al. Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary
biologic failures with IBD. Authors' reply. Aliment Pharmacol Ther 2021;53:1046-1047.
PMID: 33831234
|
 |
|
Rundquist S, Sachs MC, Eriksson C, Olen O, et al. Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary
biologic failures with IBD. Authors' reply. Aliment Pharmacol Ther 2021;53:1046-1047.
PMID: 33831234
|
|
|
|